Browsing by author "Banerjee, Susana"
Now showing items 21-32 of 32
-
Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
Friedlander, M; Banerjee, S; Mileshkin, L; Scott, C; Shannon, C; et al. (2016-12)Olaparib is the first oral poly(ADP-ribose) polymerase inhibitor to be approved as maintenance monotherapy for treatment of patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) serous ovarian cancer. This review ... -
Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
Monk, BJ; Smith, G; Lima, J; Long, GH; Alam, N; et al.<h4>Objectives</h4>To characterize clinical outcomes of women with advanced/recurrent endometrial cancer (AEC) in routine practice using electronic health records from a real-world database.<h4>Methods</h4>Adult women ... -
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Oaknin, A; Pothuri, B; Gilbert, L; Sabatier, R; Brown, J; et al. (AMER ASSOC CANCER RESEARCH, 2023-11-14)PURPOSE: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic ... -
Targeting NaPi2b in ovarian cancer.
Banerjee, S; Drapkin, R; Richardson, DL; Birrer, M (ELSEVIER SCI LTD, 2023-01-01)Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment ... -
The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II.
Lim, KHJ; Murali, K; Kamposioras, K; Punie, K; Oing, C; et al.Background The COVID-19 pandemic has resulted in significant changes to professional and personal lives of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration ... -
The integration of BRCA testing into oncology clinics.
Percival, N; George, A; Gyertson, J; Hamill, M; Fernandes, A; et al. (2016-06)Purpose The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, ... -
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Vergote, I; Van Nieuwenhuysen, E; O'Cearbhaill, RE; Westermann, A; Lorusso, D; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-12-20)PURPOSE: Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, ... -
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson, DM; Miller, A; Brady, WE; Paul, J; Carty, K; et al. (ELSEVIER SCIENCE INC, 2022-02-05)BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor ... -
Under-Treatment of Older Patients with Newly Diagnosed Epithelial Ovarian Cancer Remains an Issue.
Dumas, L; Bowen, R; Butler, J; Banerjee, S (2021-02-25)Older women with ovarian cancer have disproportionately poorer survival outcomes than their younger counterparts and receive less treatment. In order to understand where the gaps lie in the treatment of older patients, ... -
Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
Arend, RC; O'Malley, DM; Banerjee, S; McLaurin, K; Davidson, R; et al. (2021-11-02)<h4>Introduction</h4>We aimed to characterize real-world utilization of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) in women with ovarian cancer (OC).<h4>Methods</h4>This retrospective observational study of ... -
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp, AR; James, EC; McNeish, IA; Dean, A; Kim, J-W; et al. (ELSEVIER SCIENCE INC, 2022-07-01)BACKGROUND: Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and ... -
Young oncologists' perspective on the role and future of the clinician-scientist in oncology.
Lim, KHJ; Westphalen, CB; Berghoff, AS; Cardone, C; Connolly, EA; et al. (ELSEVIER, 2023-10-01)